𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

✍ Scribed by Gautam Borthakur; Yesid Alvarado; Farhad Ravandi-Kashani; Jorge Cortes; Zeev Estrov; Stefan Faderl; Percy Ivy; Carlos Bueso-Ramos; B. Nebiyou Bekele; Francis Giles

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
271 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

A Phase I study of 9-nitrocamptothecin g
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
✍ M. Dror Michaelson; David P. Ryan; Charles S. Fuchs; Jeffrey G. Supko; Rocio Gar πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

## Abstract ## BACKGROUND 9‐Nitrocamptothecin (9‐NC) is an orally available camptothecin analog with antineoplastic activity that results from the inhibition of DNA topoisomerase I. Previous studies have suggested that it has significant clinical efficacy. The primary toxicities of 9‐NC include ga